Aventis Taxotere first-line indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aventis Taxotere (docetaxel) receives approval Nov. 27 for first-line treatment of patients with unresectable locally advanced or metastatic non-small cell lung cancer in combination with cisplatin. Approval is based on a 1,218-patient clinical trial comparing Taxotere plus cisplatin or Taxotere plus carboplatin to a standard vinorelbine/cisplatin regimen. Median survival time for Taxotere/cisplatin was 10.9 months versus 10.0 months with the standard regimen. Taxotere/cisplatin yielded a 31.6% overall response compared to 24.4% for standard therap
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.